Curalc Submits Clinical Trial Application for Diabetic Nephropathy Treatment
[Asia Economy Reporter Junho Hwang] Curacle announced on the 29th that it has applied for the Phase 3 clinical trial plan (IND) for the diabetic nephropathy treatment CU01-1001 with the Ministry of Food and Drug Safety.
The company explained that this clinical trial is "a multi-center, randomized, double-blind, placebo-controlled, parallel-design Phase 3 clinical trial (Part 1) and long-term open-label extension study to evaluate the efficacy and safety of CU01-1001 administered for 24 weeks to patients with type 2 diabetic nephropathy exhibiting albuminuria."
Hot Picks Today
600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division: "Three Paychecks Under One Roof"
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Penalty Surcharges to Exceed Illicit Gains for Hoarding... Government Announces Strong Response to Market Disruption
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
They added, "The probability of the clinical trial drug receiving final approval as a pharmaceutical product is statistically known to be about 10%. Investors are advised to carefully consider the disclosed investment risks comprehensively through timely disclosures and business reports before investing."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
